SecBot SecBot
SECBOTREPLAY Home › Report › KROS

KROS · Keros Therapeutics presented additional Phase 1 data for rinvatercept…

Keros Therapeutics, Inc. · PRESS-RELEASE filed Mar 9, 2026 at 08:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Mar 9, 2026 at 08:00 ET

Keros Therapeutics presented additional Phase 1 data for rinvatercept (KER-065) at a clinical conference, showing target engagement, favorable changes in muscle and bone mass, and a good safety profile in healthy volunteers. The data support advancing rinvatercept into two Phase 2 trials for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS), representing a meaningful step in the clinical development of the drug.

  • Keros presented additional Phase 1 data for rinvatercept in healthy volunteers, confirming target engagement and mechanism of action.
  • Rinvatercept was well-tolerated with no serious adverse events or dose-limiting toxicities.
  • Treatment led to increased muscle mass, decreased fat mass, and improved bone mineral density.
  • Proteomic data showed anti-fibrotic and anti-inflammatory effects, aligning with preclinical findings.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access